DRTG(SH:600329) Shang Hai Zheng Quan Bao·2025-11-25 18:05Core Viewpoint - The announcement highlights that Tianjin Yao Daren Tang Group Co., Ltd. has received a drug registration certificate for Loxoprofen Sodium Gel Patch, marking a significant milestone in the company's strategic layout in the transdermal drug delivery field [1][2]. Drug Registration Details - Drug Name: Loxoprofen Sodium Gel Patch - Dosage Form: Patch - Specification: Each patch (14cm×10cm) contains 10g of gel, with 100mg of Loxoprofen Sodium - Registration Category: Class 4 Chemical Drug - Approval Number: National Drug Approval H20255958 - The product is approved for domestic production and meets the relevant drug registration requirements [1][2]. Market Performance and Potential - Loxoprofen Sodium Gel Patch is used for inflammation and pain relief in conditions such as osteoarthritis and muscle pain, and it has been a leading analgesic in the Chinese market [2]. - According to data from the Minai database, the product has maintained a growth rate exceeding double digits in recent years, with projected national sales exceeding 1.7 billion yuan in 2024 and over 980 million yuan in the first half of 2025 [2]. Strategic Development - The company aims to establish a modern traditional Chinese medicine patch technology platform, integrating advanced technology with traditional medicine, and plans to build a product matrix covering chemical drugs, traditional Chinese medicine, and health patches [4]. - The approval of Loxoprofen Sodium Gel Patch signifies that the product has passed the consistency evaluation for generic drugs, although it is not expected to have a significant impact on the company's recent performance [4].